S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Did You See These Trend Reversals? (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Did You See These Trend Reversals? (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Did You See These Trend Reversals? (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Did You See These Trend Reversals? (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:SNDX

Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

$21.12
+0.46 (+2.23%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$20.66
▼
$21.43
50-Day Range
$20.66
▼
$28.98
52-Week Range
$13.27
▼
$29.86
Volume
2.02 million shs
Average Volume
931,768 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.57

Syndax Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
59.0% Upside
$33.57 Price Target
Short Interest
Bearish
9.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$4.06 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.04) to ($3.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

197th out of 996 stocks

Pharmaceutical Preparations Industry

81st out of 484 stocks

See Top Rated MarketRank™ Stocks Here

SNDX stock logo

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

March 30, 2023 | finance.yahoo.com
Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
March 24, 2023 | americanbankingnews.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4%
April 2, 2023 | Legacy Research (Affiliate) (Ad)
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
March 22, 2023 | americanbankingnews.com
Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $33.57
March 15, 2023 | finance.yahoo.com
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
March 6, 2023 | finance.yahoo.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 6, 2023 | finance.yahoo.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Earnings Call Transcript
March 3, 2023 | markets.businessinsider.com
Robert W. Baird Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)
April 2, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 1, 2023 | msn.com
Expert Ratings for Syndax Pharmaceuticals
March 1, 2023 | finance.yahoo.com
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
February 27, 2023 | msn.com
Syndax Pharmaceuticals's Earnings: A Preview
February 21, 2023 | finance.yahoo.com
Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know
February 21, 2023 | finance.yahoo.com
Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023
February 14, 2023 | finance.yahoo.com
Syndax Announces Participation at Upcoming Investor Conferences
February 13, 2023 | finance.yahoo.com
Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know
February 1, 2023 | finance.yahoo.com
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
January 23, 2023 | finance.yahoo.com
Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus
January 20, 2023 | finance.yahoo.com
Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why
January 19, 2023 | finance.yahoo.com
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
January 18, 2023 | finance.yahoo.com
Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice
January 17, 2023 | finance.yahoo.com
Syndax Pharmaceuticals (SNDX) Gains As Market Dips: What You Should Know
January 17, 2023 | finance.yahoo.com
Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?
January 14, 2023 | seekingalpha.com
Syndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
January 11, 2023 | finance.yahoo.com
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
January 10, 2023 | finance.yahoo.com
bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook
January 6, 2023 | markets.businessinsider.com
J.P. Morgan Bullish on These 2 Stocks for Over 60% Upside — This Is What Makes Them Attractive
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Company Calendar

Last Earnings
2/28/2023
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNDX
CUSIP
N/A
CIK
1395937
Web
www.syndax.com
Phone
(781) 419-1400
Fax
781-419-1420
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.57
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+59.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-149,340,000.00
Net Margins
N/A
Pretax Margin
-11.02%
Return on Equity
-38.74%
Return on Assets
-35.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.85
Quick Ratio
16.85

Sales & Book Value

Annual Sales
$139.71 million
Price / Sales
10.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.76 per share
Price / Book
2.72

Miscellaneous

Outstanding Shares
68,440,000
Free Float
64,131,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
1.04

Key Executives

  • Michael A. MetzgerMichael A. Metzger
    Chief Executive Officer & Director
  • Briggs W. MorrisonBriggs W. Morrison
    President & Director
  • Keith Alan Goldan
    Chief Financial Officer & Treasurer
  • Peter OrdentlichPeter Ordentlich
    Chief Scientific Officer
  • Catherine Madigan
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SNDX Stock - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued twelve-month target prices for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they expect the company's stock price to reach $33.57 in the next year. This suggests a possible upside of 59.0% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2023?

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of 2023. Since then, SNDX stock has decreased by 17.0% and is now trading at $21.12.
View the best growth stocks for 2023 here.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SNDX earnings forecast.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02.

What ETFs hold Syndax Pharmaceuticals' stock?

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $21.12.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.45 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.

This page (NASDAQ:SNDX) was last updated on 4/2/2023 by MarketBeat.com Staff